We searched in MEDLINE, Embase, and Cochrane Library (between Jan 1, 2005, and April 30, 2017), using hepatocellular carcinoma, liver cancer, and primary liver carcinoma as free text words. We also did a manual search and review of reference lists. We largely selected publications in the past 5 years, but did not exclude commonly referenced and highly regarded older publications. Only articles published in English were selected.
SeminarHepatocellular carcinoma
Introduction
Hepatocellular carcinoma is the most frequent primary liver cancer and is an important medical problem. With 782 000 cases diagnosed and 746 000 deaths in 2012, and an age-adjusted worldwide incidence of 10·1 cases per 100 000 person-years, hepatocellular carcinoma is ranked as the sixth most common neoplasm and the third leading cause of cancer death. Hepatocellular carcinoma has been recognised as a leading cause of death among patients with cirrhosis, and its incidence is expected to increase in the future.1 Together with the recognition of its clinical relevance, major progress has been made in prevention, detection, diagnosis, and treatment. In this Seminar, we summarise the knowledge that has emerged since our last update in 2012.2
Section snippets
Epidemiology
The development of hepatocellular carcinoma is closely related to the presence of chronic liver disease. The worldwide incidence is heterogeneous because of the variable prevalence of the risk factors. Most hepatocellular carcinoma cases (80%) occur in sub-Saharan Africa and eastern Asia, where the main risk factors are chronic hepatitis B and aflatoxin B1 exposure.3 In patients with hepatitis B, the incidence of hepatocellular carcinoma increases with viral load, duration of infection, and
Pathogenesis
Development of hepatocellular carcinoma is a complex multistep process that involves sustained inflammatory damage, including hepatocyte necrosis and regeneration, associated with fibrotic deposition. Risk of hepatocellular carcinoma emerges when cirrhosis is established, and it increases in parallel to progressive liver function impairment. Hepatocellular carcinoma is the result of the accumulation of somatic genomic alterations in passenger and driver genes in addition to epigenetic
Surveillance and diagnosis
Hepatocellular carcinoma surveillance aims to reduce disease-related mortality. Several non-randomised studies have shown that patients who were enrolled into a surveillance programme were diagnosed at an earlier stage, received potential curative therapies more frequently, and had better overall survival than did unenrolled peers.30 Regrettably, these uncontrolled studies are at risk of biases.31 A randomised controlled trial32 of surveillance done in China included 18 816 patients with
Staging and prognostic assessment
Prognostic assessment is a crucial step in the management of patients with hepatocellular carcinoma. Since most patients have an associated liver disease, the prognostic evaluation should incorporate not only tumour stage, but also the degree of liver function impairment. In addition, the presence of cancer-related symptoms has consistently shown a negative effect on survival. Finally, for any system to be clinically successful, prognostic prediction should be paired with treatment indication.63
Treatment
The aim of treatment is to increase survival while maintaining the highest quality of life. Very frequently, the treatment decision pivots around what can be done, rather than what is worth being done. For that reason, it is paramount to evaluate the strength of scientific evidence of any treatment approach for selecting the most appropriate option for each patient at each tumour stage. Furthermore, achievement of the best therapeutic effectiveness requires the careful selection of candidates
Future perspectives
In the past 10 years, treatment of hepatocellular carcinoma has evolved considerably. Nowadays, patients with hepatocellular carcinoma can benefit from effective options that improve their survival whatever the evolutionary stage of disease at diagnosis. However, improvement can still be made in several areas. Prevention of the acquisition of the risk factors for development of hepatocellular carcinoma is the best strategy for decreasing mortality. The high efficacy of direct acting antivirals
Search strategy and selection criteria
For the US National Cancer Institute see https://www.cancer.gov
References (143)
- et al.
Hepatocellular carcinoma
Lancet
(2012) Epidemiology of viral hepatitis and hepatocellular carcinoma
Gastroenterology
(2012)- et al.
Alcohol and hepatocellular carcinoma
Gastroenterology
(2004) - et al.
Global trends and predictions in hepatocellular carcinoma mortality
J Hepatol
(2017) - et al.
Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team
J Hepatol
(2014) - et al.
Trends in the burden of nonalcoholic fatty liver disease in a United States cohort of veterans
Clin Gastroenterol Hepatol
(2016) - et al.
Distinctive features of hepatocellular carcinoma in non-alcoholic fatty liver disease
Lancet Gastroenterol Hepatol
(2016) - et al.
Diabetes mellitus, insulin treatment, diabetes duration, and risk of biliary tract cancer and hepatocellular carcinoma in a European cohort
Ann Oncol
(2013) - et al.
Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma
J Hepatol
(2005) - et al.
Long-term effects of hepatitis B immunization of infants in preventing liver cancer
Gastroenterology
(2016)